摘要
目的探讨瑞舒伐他汀和辛伐他汀对急性冠状动脉综合征(ACS)患者高敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)和心血管事件的影响。方法选择80例ACS患者分为瑞舒伐他汀组和辛伐他汀组各40例,在常规ACS治疗基础上,分别给予瑞舒伐他汀10 mg/d或辛伐他汀20 mg/d,观察5个月。测定两组患者血清hs-CRP和IL-6水平并观察对比心血管事件发生率。结果治疗后两组血清hs-CRP和IL-6水平均显著降低(t=6.75、6.34,4.32、4.12,P<0.05),瑞舒伐他汀治疗后显著低于辛伐他汀组(t=3.15、3.11,P<0.05)。心血管事件发生率方面瑞舒伐他汀组略低于辛伐他汀组,二者比较,差异无统计学意义(χ2=1.112,P>0.05)。结论瑞舒伐他汀和辛伐他汀均具有显著抗炎作用,都能明显减少心血管事件的发生,瑞舒伐他汀抗炎作用更显著。
Objective To explore the effects of rosuvastatin and simvastatin on hs-CRP, IL-6 and cardiovascular events in patients with acute coronary syndrome （ACS）. Methods 80 case of ACS patients were selected and randomLy divided into rosuvastatin group and simvastatin group （40 cases in each group）. They were given conventional therapy, rosuvastatin group was given rosuvastatin （10 mg/d）, and simvastatin was given simvastatin （20 mg/d） for six months. The levels of hs-CRP, IL-6 were detected, we observed the incidence of cardiovascular events during treatment. Results The levels of hs-CRP, IL-6 decreased significantly （all P〈0.05） in both groups, while the level of hs-CRP, IL-6 decreased most significantly （P〈0.05）. The incidence of cardiovascular events of rosuvastatin group was lower than simvastatin group, but difference was not significant （P〉0.05）. Conclusion Rosuvastatin and simvastatin can both decrease the levels ofhs-CRP, IL-6 in ACS patients, and decrease the incidence of cardiovascular vents. Rosuvastatin is better than simvastatin.
出处
《中国医药指南》
2014年第23期40-41,共2页
Guide of China Medicine
